Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer

Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot

(2010) Ann A. Lazar et al.   JOURNAL OF CLINICAL ONCOLOGY

Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

(2010) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

Amenorrhea from Breast Cancer Therapy — Not a Matter of Dose

(2010) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer

(2010) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?

(2008) M. M. Regan et al.   ANNALS OF ONCOLOGY

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93

(2008) Beat Thürlimann et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

(2008) Giuseppe Viale et al.   JNCI-Journal of the National Cancer Institute